Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Cordes

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Journal of Gastrointestinal Oncology|October 12, 2019
Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusionJason M Redman, Logan P Rhea, Alessandra Brofferio, et al.
Frontiers in Oncology|March 20, 2023
First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case reportMohammad O Atiq, Danielle M Pastor, Fatima Karzai, et al.
Clinical Genitourinary Cancer|June 12, 2021
Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair MutationsVincent Chau, Ravi A Madan, Marijo Bilusic, et al.
Cancer Chemotherapy and Pharmacology|September 8, 2020
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumorsKeith T Schmidt, Alwin D R Huitema, Thomas P C Dorlo, et al.
Lancet (London, England)|August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trialsDai Chihara, Ruitao Lin, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer InstituteDai Chihara, Erich P Huang, Shanda R Finnigan, et al.
Clinical Genitourinary Cancer|April 25, 2020
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide TreatmentRavi A Madan, Keith T Schmidt, Fatima Karzai, et al.
The Oncologist|May 31, 2022
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-EnzalutamideKeith T Schmidt, Fatima Karzai, Marijo Bilusic, et al.
Cancer Immunology, Immunotherapy : CII|June 17, 2026
Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastomaNyall R London, Dara Bracken-Clarke, Elisabetta Xue, et al.
Frontiers in Oncology|March 22, 2021
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast CancerMargaret E Gatti-Mays, Sofia R Gameiro, Yohei Ozawa, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Journal of Gastrointestinal Oncology|October 12, 2019
Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusionJason M Redman, Logan P Rhea, Alessandra Brofferio, et al.
Frontiers in Oncology|March 20, 2023
First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case reportMohammad O Atiq, Danielle M Pastor, Fatima Karzai, et al.
Clinical Genitourinary Cancer|June 12, 2021
Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair MutationsVincent Chau, Ravi A Madan, Marijo Bilusic, et al.
Cancer Chemotherapy and Pharmacology|September 8, 2020
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumorsKeith T Schmidt, Alwin D R Huitema, Thomas P C Dorlo, et al.
Lancet (London, England)|August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trialsDai Chihara, Ruitao Lin, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer InstituteDai Chihara, Erich P Huang, Shanda R Finnigan, et al.
Clinical Genitourinary Cancer|April 25, 2020
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide TreatmentRavi A Madan, Keith T Schmidt, Fatima Karzai, et al.
The Oncologist|May 31, 2022
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-EnzalutamideKeith T Schmidt, Fatima Karzai, Marijo Bilusic, et al.
Cancer Immunology, Immunotherapy : CII|June 17, 2026
Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastomaNyall R London, Dara Bracken-Clarke, Elisabetta Xue, et al.
Frontiers in Oncology|March 22, 2021
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast CancerMargaret E Gatti-Mays, Sofia R Gameiro, Yohei Ozawa, et al.
Pageof 4